Morning versus evening dosing of lansoprazole 30 mg daily on twenty-four-hour intragastric acidity in healthy subjects

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 4, 1996, Pages 523-527

  Fraser, A G ^a   Sawyerr, A M ^a   Hudson, M ^a   Smith, M S H ^a   Pounder, R E ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; GASTROINTESTINAL TRACT; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PH;

EID: 0030055775     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1996.33175000.x     Document Type: Article

References (17)

1. Spencer CM, Faulds D, Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994; 48: 404-30.
2. Damman HG, von-zur-Huhlen A, Balks HJ, et al. Effect of lansoprazole, 30 mg or 60 mg daily, on intragastric pH and endocrine function in healthy volunteers. Aliment Pharmacol Ther 1993; 7: 191-6.
3. Bruley-des-Varannes S, Levy P, Lartigue S, et al. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994; 8: 309-14.
4. Verdu EF, Fraser R, Armstrong D, Blum AL. Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers. Scand J Gastroenterol 1994; 29: 1065-96.
5. Avner DL, Dorsch ER, Jennings DE, Greski-Rose PA. The Lansoprazole Study Group. A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. Aliment Pharmacol Ther 1995; 9: 521-8.
6. Bardhan KD, Ahlberg J, Hislop WS, et al. Rapid healing of gastric ulcers with lansoprazole. Aliment Pharmacol Ther 1994; 8: 215-20.
7. +. ATPase inhibitor: a controlled double-blind study. Am J Gastroenterol 1993; 88: 1212-7.
8. 2-receptor antagonist therapy. Lansoprazole, a new proton pump inhibitor. Dig Dis Sci 1995; 40: 590-7.
9. Walt RP, Gomes M de Fa, Wood EC, Logan LH, Pounder RE. Effect of daily oral omprazole on 24-hour intragastric acidity. Br Med J 1983; 287: 12-7.
10. +, K( + )-ATPase inhibitor, on gastric pH and serum gastrin. Aliment Pharmacol Ther 1992; 6: 359-72.
11. Hongo M, Ohara S, Hirasawa Y, et al. Effect of lansoprazole on intragastric pH. Comparison between morning and evening dosing. Dig Dis Sci 1992; 37: 882-90.
12. Hamamuki S, Tani N, Miwa T. Clinicopharmacological study of lansoprazole on gastric acid secretion: comparison between morning and evening dosage by 24-hour intragastric Ph monitoring. Yakuri to Chiryo 1991; 19: 925-31.
13. Pounder RE, Lanzon-Miller S, Smith SH, et al. Royal Free Hospital protocol for 24-hour intragastric acidity and plasma gastrin concentration. Dig Dis 1990; 8: 10-7.
14. Barradell LB, Faulds D, McTavish D. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44: 225-50.
15. Langner B, Lemmer B. Circadian change in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects. Eur J Clin Pharmacol 1988; 33: 619-24.
16. Clench J, Reinberg A, Dziewanowska Z, Ghata J, Smolensky M. Circadian changes in the bioavailability and effects of indomethacin in healthy subjects. Eur J Clin Pharmacol 1981; 20: 359-69.
17. Hendel J, Hendel L, Aggestrup S. Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease? Aliment Pharmacol Ther 1995; 9: 693-7.